Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,15854797,ED50,"The estimated ED50 values for inhibition of PGE2 production were 0.1 and 2.0 mg/kg at 6 and 24 h, respectively.",Pharmacodynamic behaviour of the selective cyclooxygenase-2 inhibitor lumiracoxib in the lipopolysaccharide-stimulated rat air pouch model. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15854797/),[mg] / [kg],0.1,10506,DB01283,Lumiracoxib
,15854797,ED50,"The estimated ED50 values for inhibition of PGE2 production were 0.1 and 2.0 mg/kg at 6 and 24 h, respectively.",Pharmacodynamic behaviour of the selective cyclooxygenase-2 inhibitor lumiracoxib in the lipopolysaccharide-stimulated rat air pouch model. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15854797/),[mg] / [kg],2.0,10507,DB01283,Lumiracoxib
,15080766,C(max),"Arithmetic mean plasma lumiracoxib concentration-time profiles were similar for all treatments, with a rapid rise in concentration after administration, reaching C(max) values (mean +/- SD) of 9.24 +/- 1.96, 8.81 +/- 2.30, and 10.43 +/- 3.24 mg/L within 2-3 hours for treatments A, B and C, respectively.",Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080766/),[mg] / [l],9.24,28553,DB01283,Lumiracoxib
,15080766,C(max),"Arithmetic mean plasma lumiracoxib concentration-time profiles were similar for all treatments, with a rapid rise in concentration after administration, reaching C(max) values (mean +/- SD) of 9.24 +/- 1.96, 8.81 +/- 2.30, and 10.43 +/- 3.24 mg/L within 2-3 hours for treatments A, B and C, respectively.",Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080766/),[mg] / [l],8.81,28554,DB01283,Lumiracoxib
,15080766,C(max),"Arithmetic mean plasma lumiracoxib concentration-time profiles were similar for all treatments, with a rapid rise in concentration after administration, reaching C(max) values (mean +/- SD) of 9.24 +/- 1.96, 8.81 +/- 2.30, and 10.43 +/- 3.24 mg/L within 2-3 hours for treatments A, B and C, respectively.",Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080766/),[mg] / [l],10.43,28555,DB01283,Lumiracoxib
,15080766,AUC( infinity ),"AUC( infinity ) was similar for the three treatments (36.75 +/- 7.73, 34.88 +/- 8.40 and 35.50 +/- 5.72 mg.",Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080766/),mg,36.75,28556,DB01283,Lumiracoxib
,15080766,AUC( infinity ),"AUC( infinity ) was similar for the three treatments (36.75 +/- 7.73, 34.88 +/- 8.40 and 35.50 +/- 5.72 mg.",Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080766/),mg,34.88,28557,DB01283,Lumiracoxib
,15080766,AUC( infinity ),"AUC( infinity ) was similar for the three treatments (36.75 +/- 7.73, 34.88 +/- 8.40 and 35.50 +/- 5.72 mg.",Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080766/),mg,35.50,28558,DB01283,Lumiracoxib
,27430634,peak observed concentrations in the blood,2. Lumiracoxib achieved peak observed concentrations in the blood of 1.26 + 0.51 μg/mL 0.5 h (0.5-1.0) post-dose with an AUCinf of 3.48 + 1.09 μg h/mL.,Lumiracoxib metabolism in male C57bl/6J mice: characterisation of novel in vivo metabolites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27430634/),[μg] / [ml],1.26,58088,DB01283,Lumiracoxib
,27430634,AUCinf,2. Lumiracoxib achieved peak observed concentrations in the blood of 1.26 + 0.51 μg/mL 0.5 h (0.5-1.0) post-dose with an AUCinf of 3.48 + 1.09 μg h/mL.,Lumiracoxib metabolism in male C57bl/6J mice: characterisation of novel in vivo metabolites. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27430634/),[h·μg] / [ml],3.48,58089,DB01283,Lumiracoxib
,27430634,terminal half-life,Concentrations of lumiracoxib then declined with a terminal half-life of 1.54 + 0.31 h.,Lumiracoxib metabolism in male C57bl/6J mice: characterisation of novel in vivo metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27430634/),h,1.54,58090,DB01283,Lumiracoxib
,16602135,flow rate,"The analyte was separated on a reversed-phase column with acetonitrile and 0.05% trichloracetic acid in water (35:65, v/v) as mobile phase at a flow rate of 1 mL/min, and UV detection at 270 nm.",A validated high-performance liquid chromatographic assay for determination of lumiracoxib in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16602135/),[ml] / [min],1,59666,DB01283,Lumiracoxib
,16602135,retention times,"The retention times for lumiracoxib and niflumic acid (internal standard) were 16.9 and 10.4 min, respectively.",A validated high-performance liquid chromatographic assay for determination of lumiracoxib in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16602135/),min,16.9,59667,DB01283,Lumiracoxib
,16602135,retention times,"The retention times for lumiracoxib and niflumic acid (internal standard) were 16.9 and 10.4 min, respectively.",A validated high-performance liquid chromatographic assay for determination of lumiracoxib in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16602135/),min,10.4,59668,DB01283,Lumiracoxib
,15340127,AUC(0-t),"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),[h·ng] / [ml],108.0,70188,DB01283,Lumiracoxib
,15340127,maximum concentration [C(max)],"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),[ng] / [ml],26.7,70189,DB01283,Lumiracoxib
,15340127,maximum concentration [C(max)],"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),h,1.5,70190,DB01283,Lumiracoxib
,15340127,maximum concentration [C(max)],"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),[h·ng] / [ml],101.8,70191,DB01283,Lumiracoxib
,15340127,maximum concentration [C(max)],"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),[ng] / [ml],22.6,70192,DB01283,Lumiracoxib
,15340127,time to C(max),"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),[ng] / [ml],26.7,70193,DB01283,Lumiracoxib
,15340127,time to C(max),"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),h,1.5,70194,DB01283,Lumiracoxib
,15340127,time to C(max),"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),[h·ng] / [ml],101.8,70195,DB01283,Lumiracoxib
,15340127,time to C(max),"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),[ng] / [ml],22.6,70196,DB01283,Lumiracoxib
,15340127,protein binding,"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),%,57.1,70197,DB01283,Lumiracoxib
,15340127,protein binding,"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),[h·ng] / [ml],110.2,70198,DB01283,Lumiracoxib
,15340127,protein binding,"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),[ng] / [ml],27.5,70199,DB01283,Lumiracoxib
,15340127,protein binding,"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),h,1.0,70200,DB01283,Lumiracoxib
,15340127,protein binding,"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),%,53.7,70201,DB01283,Lumiracoxib
,15340127,protein binding,"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),[h·ng] / [ml],101.8,70202,DB01283,Lumiracoxib
,15340127,protein binding,"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),[ng] / [ml],22.6,70203,DB01283,Lumiracoxib
,15340127,protein binding,"Plasma methotrexate pharmacokinetics (AUC(0-t), maximum concentration [C(max)], time to C(max)) and methotrexate protein binding were similar for methotrexate alone (108.0 ng.h/mL, 26.7 ng/mL, 1.5 h, and 57.1%, respectively), methotrexate/lumiracoxib (110.2 ng.h/mL, 27.5 ng/mL, 1.0 h, and 53.7%, respectively), and methotrexate/placebo (101.8 ng.h/mL, 22.6 ng/mL, 1.0 h, and 57.0%, respectively).",Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15340127/),%,57.0,70204,DB01283,Lumiracoxib
,15070094,capsule activation times,"The mean capsule activation times for the stomach, proximal small bowel, distal small bowel, and ascending colon were 0.22, 1.52, 3.43, and 11.46 h post dose, respectively.",Assessment of lumiracoxib bioavailability from targeted sites in the human intestine using remotely activated capsules and gamma scintigraphy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15070094/),h,0.22,80254,DB01283,Lumiracoxib
,15070094,capsule activation times,"The mean capsule activation times for the stomach, proximal small bowel, distal small bowel, and ascending colon were 0.22, 1.52, 3.43, and 11.46 h post dose, respectively.",Assessment of lumiracoxib bioavailability from targeted sites in the human intestine using remotely activated capsules and gamma scintigraphy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15070094/),h,1.52,80255,DB01283,Lumiracoxib
,15070094,capsule activation times,"The mean capsule activation times for the stomach, proximal small bowel, distal small bowel, and ascending colon were 0.22, 1.52, 3.43, and 11.46 h post dose, respectively.",Assessment of lumiracoxib bioavailability from targeted sites in the human intestine using remotely activated capsules and gamma scintigraphy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15070094/),h,3.43,80256,DB01283,Lumiracoxib
,15070094,capsule activation times,"The mean capsule activation times for the stomach, proximal small bowel, distal small bowel, and ascending colon were 0.22, 1.52, 3.43, and 11.46 h post dose, respectively.",Assessment of lumiracoxib bioavailability from targeted sites in the human intestine using remotely activated capsules and gamma scintigraphy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15070094/),h,11.46,80257,DB01283,Lumiracoxib
,15070094,Cmax,The highest Cmax (2413 ng/ml) and AUC(0-infinity) for lumiracoxib were in the distal small bowel (6842 ng x h/ml).,Assessment of lumiracoxib bioavailability from targeted sites in the human intestine using remotely activated capsules and gamma scintigraphy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15070094/),[ng] / [ml],2413,80258,DB01283,Lumiracoxib
,15070094,AUC(0-infinity),The highest Cmax (2413 ng/ml) and AUC(0-infinity) for lumiracoxib were in the distal small bowel (6842 ng x h/ml).,Assessment of lumiracoxib bioavailability from targeted sites in the human intestine using remotely activated capsules and gamma scintigraphy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15070094/),[h·ng] / [ml],6842,80259,DB01283,Lumiracoxib
,15070094,AUC(0-infinity) ratio,"Effective absorption was observed from the ascending colon, with an AUC(0-infinity) ratio of 85% (69, 104)% vs. the reference.",Assessment of lumiracoxib bioavailability from targeted sites in the human intestine using remotely activated capsules and gamma scintigraphy. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15070094/),%,85,80260,DB01283,Lumiracoxib
,15177307,area under the lumiracoxib plasma concentration-time curves (AUC(0-infinity)),There were no significant differences between subjects with moderate hepatic insufficiency and healthy subjects in the area under the lumiracoxib plasma concentration-time curves (AUC(0-infinity)): 29.2 +/- 6.7 microg h ml(-1) versus 28.7 +/- 6.3 mircrog h ml(-1).,"No influence of moderate hepatic impairment on the pharmacokinetics of lumiracoxib, an oral COX-2 selective inhibitor. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15177307/),[h·μg] / [ml],29.2,81512,DB01283,Lumiracoxib
,15177307,area under the lumiracoxib plasma concentration-time curves (AUC(0-infinity)),There were no significant differences between subjects with moderate hepatic insufficiency and healthy subjects in the area under the lumiracoxib plasma concentration-time curves (AUC(0-infinity)): 29.2 +/- 6.7 microg h ml(-1) versus 28.7 +/- 6.3 mircrog h ml(-1).,"No influence of moderate hepatic impairment on the pharmacokinetics of lumiracoxib, an oral COX-2 selective inhibitor. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15177307/),[h·mircrog] / [ml],28.7,81513,DB01283,Lumiracoxib
,33991809,m/,"Mass detection was achieved in positive multiple reactions monitoring (MRM) mode, with precursor-to-product transitions at m/z 294.1 > 248.1, m/z 310.1 > 264.1, m/z 470.1 > 276.1 and m/z 296.0 > 250.0 for lumiracoxib, 4'-hydroxyl-lumiracoxib, lumiracoxib-acyl-glucuronide and for IS, respectively.",A validated UHPLC-MS/MS method for simultaneous determination of lumiracoxib and its hydroxylation and acyl glucuronidation metabolites in rat plasma: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33991809/),,310.1,88086,DB01283,Lumiracoxib
,33991809,m/,"Mass detection was achieved in positive multiple reactions monitoring (MRM) mode, with precursor-to-product transitions at m/z 294.1 > 248.1, m/z 310.1 > 264.1, m/z 470.1 > 276.1 and m/z 296.0 > 250.0 for lumiracoxib, 4'-hydroxyl-lumiracoxib, lumiracoxib-acyl-glucuronide and for IS, respectively.",A validated UHPLC-MS/MS method for simultaneous determination of lumiracoxib and its hydroxylation and acyl glucuronidation metabolites in rat plasma: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33991809/),,264.1,88087,DB01283,Lumiracoxib
,33991809,m/z,"Mass detection was achieved in positive multiple reactions monitoring (MRM) mode, with precursor-to-product transitions at m/z 294.1 > 248.1, m/z 310.1 > 264.1, m/z 470.1 > 276.1 and m/z 296.0 > 250.0 for lumiracoxib, 4'-hydroxyl-lumiracoxib, lumiracoxib-acyl-glucuronide and for IS, respectively.",A validated UHPLC-MS/MS method for simultaneous determination of lumiracoxib and its hydroxylation and acyl glucuronidation metabolites in rat plasma: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33991809/),,470.1,88088,DB01283,Lumiracoxib
>,33991809,m/z,"Mass detection was achieved in positive multiple reactions monitoring (MRM) mode, with precursor-to-product transitions at m/z 294.1 > 248.1, m/z 310.1 > 264.1, m/z 470.1 > 276.1 and m/z 296.0 > 250.0 for lumiracoxib, 4'-hydroxyl-lumiracoxib, lumiracoxib-acyl-glucuronide and for IS, respectively.",A validated UHPLC-MS/MS method for simultaneous determination of lumiracoxib and its hydroxylation and acyl glucuronidation metabolites in rat plasma: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33991809/),,276.1,88089,DB01283,Lumiracoxib
,33991809,m/z,"Mass detection was achieved in positive multiple reactions monitoring (MRM) mode, with precursor-to-product transitions at m/z 294.1 > 248.1, m/z 310.1 > 264.1, m/z 470.1 > 276.1 and m/z 296.0 > 250.0 for lumiracoxib, 4'-hydroxyl-lumiracoxib, lumiracoxib-acyl-glucuronide and for IS, respectively.",A validated UHPLC-MS/MS method for simultaneous determination of lumiracoxib and its hydroxylation and acyl glucuronidation metabolites in rat plasma: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33991809/),,296.0,88090,DB01283,Lumiracoxib
>,33991809,m/z,"Mass detection was achieved in positive multiple reactions monitoring (MRM) mode, with precursor-to-product transitions at m/z 294.1 > 248.1, m/z 310.1 > 264.1, m/z 470.1 > 276.1 and m/z 296.0 > 250.0 for lumiracoxib, 4'-hydroxyl-lumiracoxib, lumiracoxib-acyl-glucuronide and for IS, respectively.",A validated UHPLC-MS/MS method for simultaneous determination of lumiracoxib and its hydroxylation and acyl glucuronidation metabolites in rat plasma: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33991809/),,250.0,88091,DB01283,Lumiracoxib
more,33991809,extraction recovery,The extraction recovery was more than 80.54 %.,A validated UHPLC-MS/MS method for simultaneous determination of lumiracoxib and its hydroxylation and acyl glucuronidation metabolites in rat plasma: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33991809/),%,80.54,88092,DB01283,Lumiracoxib
,16372823,acid dissociation constant [pKa],"Lumiracoxib possesses a carboxylic acid group that makes it weakly acidic (acid dissociation constant [pKa] 4.7), distinguishing it from other selective COX-2 inhibitors.",Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372823/),,4.7,89509,DB01283,Lumiracoxib
,16372823,oral bioavailability,Lumiracoxib has good oral bioavailability (74%).,Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372823/),%,74,89510,DB01283,Lumiracoxib
,16372823,elimination half-life,Lumiracoxib has a short elimination half-life from plasma (mean 4 hours) and demonstrates dose-proportional plasma pharmacokinetics with no accumulation during multiple dosing.,Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372823/),h,4,89511,DB01283,Lumiracoxib
,19958362,dissociation equilibrium constant,The in vivo estimate of the dissociation equilibrium constant of the COX-2-lumiracoxib complex was 0.24 microg*mL(-1).,"Pharmacokinetic-pharmacodynamic modelling of the analgesic effects of lumiracoxib, a selective inhibitor of cyclooxygenase-2, in rats. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19958362/),[μg] / [ml],0.24,102841,DB01283,Lumiracoxib
,28351678,peak observed concentrations in the blood,"In the chimeric humanized mice, lumiracoxib reached peak observed concentrations in the blood of 1.10±0.08μg/mL at 0.25-0.5h post-dose with an AUCinf of 1.74±0.52μgh/mL and an effective half-life for the drug of 1.42±0.72h (n=3).",The pharmacokinetics and metabolism of lumiracoxib in chimeric humanized and murinized FRG mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28351678/),[μg] / [ml],1.10,120584,DB01283,Lumiracoxib
,28351678,AUCinf,"In the chimeric humanized mice, lumiracoxib reached peak observed concentrations in the blood of 1.10±0.08μg/mL at 0.25-0.5h post-dose with an AUCinf of 1.74±0.52μgh/mL and an effective half-life for the drug of 1.42±0.72h (n=3).",The pharmacokinetics and metabolism of lumiracoxib in chimeric humanized and murinized FRG mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28351678/),[μgh] / [ml],1.74,120585,DB01283,Lumiracoxib
,28351678,effective half-life,"In the chimeric humanized mice, lumiracoxib reached peak observed concentrations in the blood of 1.10±0.08μg/mL at 0.25-0.5h post-dose with an AUCinf of 1.74±0.52μgh/mL and an effective half-life for the drug of 1.42±0.72h (n=3).",The pharmacokinetics and metabolism of lumiracoxib in chimeric humanized and murinized FRG mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28351678/),h,1.42,120586,DB01283,Lumiracoxib
,28351678,peak observed concentrations,In the case of the murinized animals peak observed concentrations in the blood were determined as 1.15±0.08μg/mL at 0.25h post-dose with an AUCinf of 1.94±0.22μgh/mL and an effective half-life of 1.28±0.02h (n=3).,The pharmacokinetics and metabolism of lumiracoxib in chimeric humanized and murinized FRG mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28351678/),[μg] / [ml],1.15,120587,DB01283,Lumiracoxib
,28351678,AUCinf,In the case of the murinized animals peak observed concentrations in the blood were determined as 1.15±0.08μg/mL at 0.25h post-dose with an AUCinf of 1.94±0.22μgh/mL and an effective half-life of 1.28±0.02h (n=3).,The pharmacokinetics and metabolism of lumiracoxib in chimeric humanized and murinized FRG mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28351678/),[μgh] / [ml],1.94,120588,DB01283,Lumiracoxib
,28351678,effective half-life,In the case of the murinized animals peak observed concentrations in the blood were determined as 1.15±0.08μg/mL at 0.25h post-dose with an AUCinf of 1.94±0.22μgh/mL and an effective half-life of 1.28±0.02h (n=3).,The pharmacokinetics and metabolism of lumiracoxib in chimeric humanized and murinized FRG mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28351678/),h,1.28,120589,DB01283,Lumiracoxib
,15655513,K(i),"2. Lumiracoxib inhibited purified COX-1 and COX-2 with K(i) values of 3 and 0.06 microM, respectively.",Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15655513/),μM,3,123524,DB01283,Lumiracoxib
,15655513,K(i),"2. Lumiracoxib inhibited purified COX-1 and COX-2 with K(i) values of 3 and 0.06 microM, respectively.",Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15655513/),μM,0.06,123525,DB01283,Lumiracoxib
,15655513,IC(50),"In cellular assays, lumiracoxib had an IC(50) of 0.14 microM in COX-2-expressing dermal fibroblasts, but caused no inhibition of COX-1 at concentrations up to 30 microM (HEK 293 cells transfected with human COX-1).",Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15655513/),μM,0.14,123526,DB01283,Lumiracoxib
,15655513,IC(50),"3. In a human whole blood assay, IC(50) values for lumiracoxib were 0.13 microM for COX-2 and 67 microM for COX-1 (COX-1/COX-2 selectivity ratio 515).",Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15655513/),μM,0.13,123527,DB01283,Lumiracoxib
,15655513,IC(50),"3. In a human whole blood assay, IC(50) values for lumiracoxib were 0.13 microM for COX-2 and 67 microM for COX-1 (COX-1/COX-2 selectivity ratio 515).",Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15655513/),μM,67,123528,DB01283,Lumiracoxib
,15655513,selectivity ratio,"3. In a human whole blood assay, IC(50) values for lumiracoxib were 0.13 microM for COX-2 and 67 microM for COX-1 (COX-1/COX-2 selectivity ratio 515).",Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15655513/),,515,123529,DB01283,Lumiracoxib
,15655513,ID(50),"5. Ex vivo, lumiracoxib inhibited COX-1-derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1).",Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15655513/),[mg] / [kg],33,123530,DB01283,Lumiracoxib
,15655513,ID(50),"5. Ex vivo, lumiracoxib inhibited COX-1-derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1).",Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15655513/),[mg] / [kg],0.24,123531,DB01283,Lumiracoxib
,15139795,terminal elimination half-life,Lumiracoxib was rapidly absorbed (peak plasma concentration at 2 hours) and the terminal elimination half-life in plasma was short (6 hours).,Pharmacokinetics of lumiracoxib in plasma and synovial fluid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15139795/),h,6,177383,DB01283,Lumiracoxib
,15139795,steady-state trough concentration,"The mean steady-state trough concentration of lumiracoxib in synovial fluid (454 microg/L) was approximately three times higher than the mean value in plasma (155 microg/L), and the area under the concentration-time curve from 12 to 24 hours after administration was 2.6-fold higher for synovial fluid than for plasma.",Pharmacokinetics of lumiracoxib in plasma and synovial fluid. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15139795/),[μg] / [l],454,177384,DB01283,Lumiracoxib
,15139795,steady-state trough concentration,"The mean steady-state trough concentration of lumiracoxib in synovial fluid (454 microg/L) was approximately three times higher than the mean value in plasma (155 microg/L), and the area under the concentration-time curve from 12 to 24 hours after administration was 2.6-fold higher for synovial fluid than for plasma.",Pharmacokinetics of lumiracoxib in plasma and synovial fluid. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15139795/),[μg] / [l],155,177385,DB01283,Lumiracoxib
,15139795,protein binding,Median lumiracoxib protein binding was similar in plasma and synovial fluid (range 97.9-98.3%).,Pharmacokinetics of lumiracoxib in plasma and synovial fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15139795/),%,97.9-98.3,177386,DB01283,Lumiracoxib
>,15100180,mean plasma concentrations,"Lumiracoxib was rapidly absorbed, achieving mean plasma concentrations >1 microg/ml within 1 h of dosing.",Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15100180/),[μg] / [ml],1,183734,DB01283,Lumiracoxib
,15100180,terminal half-life,The terminal half-life of lumiracoxib in plasma was 6.5 h.,Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15100180/),h,6.5,183735,DB01283,Lumiracoxib
